0000000001170756

AUTHOR

M. A. Bort-martí

showing 1 related works from this author

Tocilizumab as first treatment option in optic neuropathy secondary to Graves' orbitopathy.

2018

Dysthyroid optic neuropathy (DON) is one of the complications that can affect Graves' orbitopathy (GO) patients. Its prevalence is estimated at less than 5%. It is usually treated with intravenous steroids, radiotherapy or orbital decompression. Tocilizumab has been proposed as a treatment option in cases of GO refractory to steroid treatment, with good clinical results. Our aim is to report the case of a patient with optic neuropathy secondary to GO treated with tocilizumab as primary treatment option.

Malemusculoskeletal diseasesDecompressionmedicine.medical_specialtyDecompressionmedicine.medical_treatmentVisual Acuity030209 endocrinology & metabolismdysthyroid optic neuropathyAntibodies Monoclonal HumanizedOptic neuropathy03 medical and health scienceschemistry.chemical_compoundGraves' orbitopathytocilizumab0302 clinical medicineTocilizumabRefractoryOptic Nerve DiseasesmedicineHumansbusiness.industryTreatment optionsMiddle Agedmedicine.diseaseeye diseasesSurgeryRadiation therapyGraves OphthalmopathyOphthalmologychemistry030221 ophthalmology & optometryPrimary treatmentVisual FieldsIntravenous steroidsbusinessTomography Optical Coherencesteroids
researchProduct